Navigation Links
Halozyme Therapeutics to Present at Upcoming Investor Conferences
Date:10/22/2008

SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will present at three upcoming investor conferences:

-- BIOCOM Investor Conference to be held at the Hyatt Regency in La Jolla, Calif. on Monday, October 27, 2008 at 2:00 p.m. PDT (5:00 p.m. EDT);

-- Oppenheimer's 19th Annual Healthcare Conference to be held at the Waldorf-Astoria Hotel in New York on Monday, November 3, 2008 at 10:40 a.m. EST (7:40 a.m. PST); and

-- Lazard Capital Markets 5th Annual Healthcare Conference to be held at the St. Regis Hotel in New York on Tuesday, November 18, 2008 at 2:40 p.m. EST (11:40 a.m. PST).

Interested parties can access a live audio webcast and accompanying slides of the conference presentations via the internet by visiting the Investor Relations section of Halozyme's website at http://www.halozyme.com. Archived presentations will be available on the website for 30 days following the presentation dates.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology, and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic product, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme also has a number of additional enzymes in its portfolio that target significant areas of unmet medical need. For more information visit http://www.halozyme.com.

Halozyme Contact Media Contacts

Robert H. Uhl Karen Sparks / Joleen Schultz

Senior Director, Investor Relations Mentus

(858) 704-8264 (858) 455-5500, x275/x215

ruhl@halozyme.com karen@mentus.com jschultz@mentus.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics to Host Research Day for Investors and Analysts
2. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
5. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
6. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
7. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
8. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
9. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
10. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
11. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology:
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
Breaking Biology News(10 mins):